Vascular endothelial growth factor and corpus luteum angiogenesis

Angiogenesis

Volumn 2, Issue 2, 1998, Pages 119-121

  Charnock Jones, D Stephen ^a   Smith, Stephen K ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0004574483     PISSN: 09696970     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009232320991     Document Type: Short Survey

References (13)

1. Ferrara N, Chen H, Davis Smyth T, et al. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat Med 1998; 4, 336-340.
2. Zheng J, Redmer DA, Reynolds LP. Vascular development and heparin-binding growth factors in the bovine corpus luteum at several stages of the estrous cycle. Biol Reprod 1993; 49, 1177-1189.
3. Rogers PA, Au CL, Affandi B. Endometrial microvascular density during the normal menstrual cycle and following exposure to long-term levonorgestrel. Hum Reprod 1993; 8, 1396-1404.
4. Klauber N, Rohan RM, Flynn E, D'Amato RJ. Critical components of the female reproductive pathway are suppressed by the angiogenesis inhibitor AGM-1470. Nat Med 1997; 3, 443-446.
5. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362, 841-844.
6. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 1993; 90, 10705-10709.
7. Boocock CA, Charnock-Jones DS, Sharkey AM, et al. Expression of vacular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst 1995; 87, 506-516.
8. Davis-Smyth T, Chen H, Park J, Presta LG, Ferrara N. The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade. EMBO J 1996; 15, 4919-4927.
9. Barleon B, Totzke F, Herzog C, et al. Mapping of the sites for ligand binding and receptor dimerization at the extracellular domain of the vascular endothelial growth factor receptor FLT-1. J Biol Chem 1997; 272, 10382-10388.
10. Capon DJ, Chamow SM, Mordenti J, et al. Designing CD4 immunoadhesins for AIDS therapy. Nature 1989; 337, 525-531.
11. Benjamin LE, Keshet E. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc Natl Acad Sci USA 1997; 94, 8761-8766.
12. Jakeman LB, Armanini M, Phillips HS, Ferrara N. Developmental expression of binding sites and messenger ribonucleic acid for vascular endothelial growth factor suggests a role for this protein in vasculogenesis and angiogenesis. Endocrinology 1993; 133, 848-859.
13. Ferrara N, Davis Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997; 18, 4-25.